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Abstract
 
Antibodies that bind to antigens expressed on the merozoite form of the malaria parasite can
inhibit parasite growth by preventing merozoite invasion of red blood cells. Inhibitory anti-
bodies are found in the sera of malaria-immune individuals, however, the specificity of those
that are important to this process is not known. In this paper, we have used allelic replacement
to construct a 
 
Plasmodium falciparum
 
 parasite line that expresses the complete COOH-terminal
fragment of merozoite surface protein (MSP)-1
 
19
 
 from the divergent rodent malaria 
 
P. cha-
baudi
 
. By comparing this transfected line with parental parasites that differ only in MSP-1
 
19
 
,
we show that antibodies specific for this domain are a major component of the inhibitory re-
sponse in 
 
P. falciparum
 
–immune humans and 
 
P. chabaudi
 
–immune mice. In some individual
human sera, MSP-1
 
19
 
 antibodies dominated the inhibitory activity. The finding that antibodies
to a small region of a single protein play a major role in this process has important implications
for malaria immunity and is strongly supportive of further understanding and development of
MSP-1
 
19
 
–based vaccines.
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Introduction
 
Infection by the protozoan parasite 
 
Plasmodium falciparum
 
results in several hundred million clinical cases of malaria
each year of which approximately two million are fatal.
The development of a malaria vaccine is now a major glo-
bal initiative. Progress toward this goal requires an under-
standing of the mechanisms that underpin both naturally
acquired and vaccine-induced immunity. Antibodies that
inhibit the growth of bloodstage 
 
P. falciparum
 
 parasites in
vitro are found in the sera of some, but not all, individuals
living in malaria endemic regions (1–4). Inhibitory anti-
bodies are likely to contribute to the clinical immunity ob-
served in highly exposed individuals but their overall sig-
nificance to protection remains unclear (5, 6).
Inhibitory antibodies function by preventing invasion of
RBCs by the extracellular merozoite form of the parasite.
A number of merozoite antigens have been shown to be
targets of invasion inhibitory antibodies including some
that localize to the merozoite surface, parasitophorous vac-
uole, and apical organelles. One target of inhibitory anti-
bodies is the membrane-associated 19-kD COOH-termi-
nal fragment of merozoite surface protein (MSP)
 
1
 
-1
 
19
 
, a
molecule that is now a leading malaria vaccine candidate
(7, 8). MSP-1
 
19
 
 is composed almost entirely of two cys-
teine-rich epidermal growth factor (EGF)-like domains
that form a tightly packed, disc-like structure (9, 10). The
function of MSP-1
 
19
 
 is unknown, however, allelic replace-
ment experiments have shown that the function of most of
the two EGF domains is conserved across distantly related
 
Plasmodium
 
 species (11).
The MSP-1
 
19
 
 EGF domains form reduction-sensitive
epitopes that are recognized by invasion-inhibitory mono-
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transferase; HNIS, human nonimmune sera; IFA, immunoflu-
orescence assay; MSP, merozoite surface protein; OD, optical density. 
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clonal and polyclonal antibodies (11–15). MSP-1
 
19
 
–specific
inhibitory antibodies are also present in the sera of individ-
uals naturally exposed to 
 
P. falciparum
 
 (16). These antibod-
ies recognize epitopes formed by the double EGF domain
and by the second EGF domain alone (16). The mechanism
of inhibition by MSP-1
 
19
 
 antibodies is not fully understood,
however, those that prevent the secondary processing of a
precursor molecule and hence the formation of MSP-1
 
19
 
also effectively inhibit merozoite invasion of RBCs (17).
Here, by constructing a transfected 
 
P. falciparum
 
 line that
expresses an antigenically distinct MSP-1
 
19
 
 domain from
the distantly related species 
 
P. chabaudi
 
, we show that MSP-
1
 
19
 
–specific antibodies comprise a large component of the
total invasion–inhibitory response of sera from many 
 
P. fal-
ciparum
 
–immune adults from Papua New Guinea. Also, we
show that considerable amounts of MSP-1
 
19
 
–inhibitory an-
tibodies are elicited in mice experimentally infected with a
rodent malaria parasite 
 
P. chabaudi
 
. This is the first time that
the relative contribution of specific antibodies to the inva-
sion-inhibitory activity of immune sera has been examined.
 
Materials and Methods
 
Plasmids.
 
Construction of the plasmids pPfM3
 
 
 
 and pPcM3
 
 
 
has been described previously (11). The plasmid pPcMEGF was
constructed by the insertion of a 1,200-bp XhoI fragment into
the unique XhoI site of a plasmid pHC2 (18). This target frag-
ment comprises a 900-bp internal region of the 
 
P. falciparum
 
MSP-1 gene fused in frame to the MSP-1
 
19 
 
region of 
 
P. chabaudi
 
.
The fragment was generated by PCR amplification from 
 
P. falci-
parum
 
 (D10) and 
 
P. chabaudi
 
 (adami DS) genomic DNA (gDNA)
using the oligonucleotide pairs Pf#1 5
 
 
 
-ATTT
 
CTCGAG-
 
AATCCGAAGATAATGACG-3
 
 
 
, PfEGF-R 5
 
 
 
-GAAACATC-
CAGCATTTTCTGGAAGTTTGTTCCTATGCATTGGTG-
TTGTGAAATG-3
 
 
 
, and PcEGF-F 5
 
 
 
-CCAGAAAATGC-
TGGATGTTTCAGATATGATGATGGTAAAGAAGAATG-
G-3
 
 
 
, Pc3
 
  
 
5
 
 
 
-TCA
 
CTCGAG
 
TTAAAATAAATTAAATACA-
ATTAATGTG-3
 
 
 
. The resulting amplicons were sewn together
via PCR for insertion into pHC2. The XhoI sites are shown in
bold.
 
Parasite Culture and Transfection Procedures. P.  falciparum
 
 line
D10 was cultivated and synchronized as per standard procedures
(19, 20). Ring-stage parasites (
 
 
 
5% parasitemia) were transfected
with 50–100 
 
 
 
g of CsCl-purified plasmid DNA as described pre-
viously (21, 22) but using the electroporation conditions as de-
scribed by Fidock and Wellems (23). After transfection and initial
selection using 0.1 
 
 
 
M pyrimethamine for 
 
 
 
4 wk, parasites were
subjected to repeated cycles of 1 
 
 
 
M pyrimethamine for 3 wk
proceeded by removal of the drug for 3–4 wk. gDNA was ex-
tracted from mixed trophozoite/schizont stage parasites as de-
scribed previously (24), and Southern blot analysis was carried out
using standard procedures (25).
 
Western Blot Analysis.
 
Parasite proteins were obtained from
extracted enriched schizont or merozoite preparations and sepa-
rated using 7.5 and 12% SDS-PAGE nonreducing gels, respec-
tively, and transferred to PVDF membranes (Amersham Pharma-
cia Biotech). Membranes were probed with either mouse ascitic
fluid containing 4H9/19, a monoclonal antibody specific for 
 
P.
falciparum
 
 MSP-1
 
19
 
 (14), diluted 1:80,000 or rabbit 
 
 
 
PcM19
polyclonal antibodies diluted 1:2,500 that are specific for 
 
P. cha-
baudi 
 
MSP-1
 
19
 
 (11). Horseradish peroxidase–conjugated rabbit
anti–mouse (Dako) or sheep anti–rabbit (Silenus) Igs were used
for detection, and bands were visualized by enhanced chemilumi-
nescence (NEN Life Science Products).
 
Indirect Immunofluorescence.
 
For indirect immunofluorescence
assay (IFA), D10-PfM3
 
 
 
 and D10-PcMEGF schizont-stage para-
sites were incubated with a mixture of 4H9/19 ascitic fluid and
 
 
 
PcM19 sera diluted 1:4,000 and 1:1,000, respectively. After in-
cubation in the presence of a mixture of FITC-conjugated sheep
anti–mouse and rhodamine-conjugated goat anti–rabbit Igs
(Dako), both diluted 1:150, parasites were visualized by fluores-
cence microscopy. The same fields were photographed using fil-
ters to detect the FITC or rhodamine fluorochromes.
 
Sera.
 
The Papua New Guinean sera used were collected in
the Madang Province from adults living in and around Madang
town in 1980–82 (denoted PNG-M sera) and from adults cur-
rently living on Bagabag Island (denoted PNG-B sera). Both lo-
cations have high prevalence rates of 
 
P. falciparum
 
 (over all rates of
25.7 and 24%, respectively, with the highest rates observed in 1–9
yr-old children in both communities) that are indicative of in-
tense transmission (26). Transmission in these localities is peren-
nial with similar rates in the wet and dry seasons.
To generate 
 
P. chabaudi
 
 immune mouse sera (
 
Pc
 
 immune), six
7-wk-old C57BL/6 male mice were injected intraperitoneally
with 5 
 
 
 
 10
 
3
 
 
 
P. chabaudi
 
 (adami DS)–infected RBCs and rechal-
lenged at 3 wk with the same dose. At weeks 7 and 21, mice
were administered a higher challenge of 10
 
4
 
 
 
P. chabaudi
 
–infected
RBCs before serum collection at week 24.
 
MSP-1
 
19
 
 Glutathione S Transferase Fusion Proteins.
 
The DNA
sequence corresponding to the MSP-1
 
19
 
 fragment lacking the
glycosylphosphatidylinositol anchor sequence (amino acids Asn
1631–Ser 1723, according to reference 27) was amplified from 
 
P.
falciparum
 
 D10 or HB3 gDNA (which contains the MAD20 or
K1 MSP-1
 
19 
 
alleles, respectively; reference 27) using the oligonu-
cleotides: PfM19f 5
 
 
 
-CGCGGATCCAACATTTCACAACAC-
CAATGCG-3
 
 
 
 and PfM19r 5
 
 
 
-GGAAGATCTTAACTGCA-
GAAAATACCATCGAAAAG-3
 
 
 
. The corresponding sequence
was amplified from 
 
P. chabaudi
 
 (adami DS) gDNA using the oli-
gonucleotides: PcM19f 5
 
 
 
-CGCGGATCCGGTATAGGT-
TCTAATCATGTATG-3
 
 
 
 and PcM19r 5
 
 
 
-GGAAGATCT-
TAGCTACAGAATACACCATCATAAT-3
 
 
 
. The resulting
PCR products were ligated into the BamHI site of pGEX-4T-1,
expressed as glutathione 
 
S
 
 transferase (GST) fusion proteins in
 
Escherichia coli
 
 (28) and purified using glutathine-sepharose as de-
scribed by the manufacturer (Amersham Pharmacia Biotech).
GST alone was produced using the pGEX-4T-1 plasmid.
 
ELISA.
 
Antibodies reacting with recombinant 
 
P. falciparum
 
MSP-1
 
19
 
 and 
 
P. chaubaudi
 
 MSP-1
 
19
 
 were detected by ELISA. Mi-
crotitre plates (Dynex) were coated overnight at 4
 
 
 
C with 0.5
 
 
 
g/ml recombinant protein diluted in carbonate buffer (0.015 M
Na
 
2
 
CO
 
3
 
, 0.035 M NaHCO
 
3
 
, pH 9.6). Plates were washed three
times with PBS containing 0.05% Tween 20 (PBST), blocked for
2 h at 37
 
 
 
C with PBST containing 10 mg/ml BSA, and washed
again. Sera diluted in PBST containing 5 mg/ml BSA was then
added to the plates (50 
 
 
 
l), which were then incubated further
for 1 h at 37
 
 
 
C. After washing with PBST, horseradish peroxi-
dase–conjugated sheep anti–human IgG (1:4,000; Silenus), rabbit
anti–mouse IgG (1:5,000), or sheep anti–rabbit IgG (1:2,500;
Dako) were added to the plates, incubated for 1 h at 37
 
 
 
C and,
after washing with PBST, developed with H2O2 and 3,3 ,5,5 -
tetramethylbenzidine dihydrochloride for 10 min at room tem-
perature. The reaction was stopped by the addition of 20  l
2.5 M H2SO4 and plates were read at 450 nm. All human and mouse1405 O’Donnell et al.
sera were tested in duplicate at three dilutions (1:1,000, 1:3,200,
and 1:10,000) against GST-PfM19, GST-PcM19, and GST alone.
The mean optical density (OD) value derived for GST alone was
subtracted from the mean OD obtained for each GST fusion pro-
tein. Values at a 1:3,200 dilution were considered most likely to
be on the slope of a titration curve, hence, these values are repre-
sented here.
Inhibition of Invasion Assays. Ring-stage parasites were syn-
chronized by sorbitol lysis twice at 4-h intervals and then allowed
to mature through to trophozoite/schizont stages. The purified
parasites were adjusted to 4% hematocrit with 0.5–2% infected
RBCs and aliquots of 50  l placed into the wells of a 96-well
tray. An equal volume of serum, prediluted 1:10 in culture media,
was added (resultant hematocrit of 2%) and cultures incubated for
 26 h to allow for schizont rupture and merozoite invasion.
Note that when two parasite lines were being compared the same
batch of prediluted serum was added to each line. For the micros-
copy analysis, smears were made of the duplicate wells, stained
with Giemsa, and the number of ring-stage parasites per 500
RBCs were determined for each well. The mean parasitemia
from duplicate wells was calculated and this was expressed as a
percentage of the mean parasitemia observed in parallel cultures
of each parasite line in the presence of pooled human nonim-
mune sera (HNIS). For the [3H]hypoxanthine uptake assay, me-
dia was removed from triplicate wells at  24 h after cultivation
and replaced with hypoxanthine-free media supplemented with
[3H]hypoxanthine (10  Ci/ml). A further 24 h later, cultures of
mature parasites were frozen and thawed to lyse infected RBCs.
Samples were transferred to glass fiber filters via a cell harvester
and quantitated using a scintillation counter. Statistical analysis to
address whether the mean invasion rates of these sera were the
same between two lines was performed using a two-sample Stu-
dent’s t test assuming unequal variances.
Cocultivation Assays. For cocultivation, D10-PfM3  and D10-
PcMEGF ring-stage parasites were doubly synchronized as de-
scribed above and then cultured together at an equal ratio in
the presence of pooled sera. Sera was pooled on the basis of ei-
ther appearing to contain significant proportions of anti–MSP-
119 inhibitory antibodies (pool 2) or having a less inhibitory effect
between the two parasite lines (pool 1). The pools included the
following sera: (PNG-B pool 1) 8, 247, 322, and 962; (PNG-B
pool 2) 413, 604, 614, and 954; (Pc-immune pool 1) 2 and 4; and
(Pc-immune pool 2) 1, 3, 5, and 6. Additional controls included a
HNIS pool and  PcM19 rabbit serum. Parasites were smeared at
the trophozoite/schizont stage (i.e., every 2 d beginning at day 1)
and assessed by indirect IFA using a mixture of 4H9/19 and
 PcM19 as described above. For each of the triplicate slides,
FITC (D10-PfM3 ) and rhodamine (D10-PcMEGF) were ob-
served and counted in 16 individual fields that each contained at
least 10 mature (pigmented) parasites. In total, between 400 and
1,400 mature stage parasites were counted for each cocultivation
sample.
Results
Replacement of Complete EGF Domains of P. falciparum
MSP-119 with those from P. chabaudi. The aim of this study
was to generate a P. falciparum line that possesses an antigen-
ically distinct MSP-119 domain and to investigate whether
this line differs from parental parasites in its susceptibility to
inhibition by sera from malaria-immune individuals. We
have described previously the construction of a parasite line
D10-PcM3  which expresses an MSP-1 chimera in place of
the endogenous molecule (11). This chimera incorporates
 3/4 of the two EGF-like domains that comprise MSP-119
from the divergent rodent malaria P. chabaudi (Fig. 1 A).
We also constructed a control transfectant D10-PfM3 
which expresses endogenous MSP-1 (Fig. 1 A; reference
11). These transfected lines displayed no observable pheno-
typic differences to parental D10 parasites revealing that the
function of most of MSP-119 is conserved across divergent
Plasmodium species. Here we describe transfection of a plas-
mid, pPcMEGF, designed to replace the entire EGF do-
mains from MSP-119 with those from P. chabaudi (Fig. 1).
Upon transfection and drug cycling, pPcMEGF was shown
to have integrated into the MSP-1 gene. The transfected
population, D10-PcMEGF, was cloned and two randomly
selected clones (D10-PcMEGF.1 and D10-PcMEGF.2)
were analyzed further. Southern blot analysis showed the
plasmid had integrated into the target site through the ex-
pected recombination event replacing the entire endoge-
nous P. falciparum MSP-119 EGF domains with those from
P. chabaudi. This line could be distinguished from both
D10-PfM3  and D10-PcM3  by restriction endonuclease
digestion with XbaI (Fig. 1, B and C).
To determine if the chimeric MSP-1 was expressed in
D10-PcMEGF parasites, extracts of mature schizonts and
free merozoites were examined by immunoblot analysis
(Fig. 2 A). Bands corresponding to endogenous full-length
MSP-1 ( 200 kD) and MSP-119 ( 18 kD) were detected
in parental D10 schizonts and merozoites, respectively, us-
ing the P. falciparum–specific antibody 4H9/19 (14). No re-
active bands were observed in extracts from the two D10-
PcMEGF clones. Conversely, when replicate immunoblots
were probed with a rabbit antiserum specific for P. chabaudi
MSP-119 ( PcM19; reference 11), species corresponding to
both forms of MSP-1 were observed in the D10-PcMEGF
extracts but not in parental D10 (Fig. 2 A). The larger band
( 40 kD) in the merozoite samples is consistent with the
presence of the primary MSP-1 processing product, MSP-
142. The localization of the MSP-1 chimera was assessed by
an IFA (Fig. 2 B). D10-PfM3  and D10-PcMEGF parasites
were incubated with a mixture of mouse 4H9/19 and rab-
bit   PcM19 antibodies followed by FITC-labeled anti–
mouse (to detect endogenous MSP-1) and rhodamine-
labeled anti–rabbit (to detect the MSP-1 chimera) IgG.
“Grape-like” fluorescence was observed in both lines in-
dicative of merozoite surface labeling. D10-PcMEGF para-
sites showed only rhodamine fluorescence supporting the
absence of endogenous MSP-119 expression in this line.
Fluorescence was also observed in ring-stage parasites indi-
cating that the P. chabaudi MSP-119 domain is carried into
the newly invaded RBCs in D10-PcMEGF parasites as has
been described for P. falciparum MSP-119 (data not shown;
references 11 and 12).
To ensure that the chimeric MSP-1 was functional, an in
vitro inhibition of invasion assay was carried out (Fig. 2 C).
Mature stage parasites from parental D10, D10-PcM3 , and1406 Inhibitory MSP-119 Antibodies Are a Major Component of Malaria-immune Sera
two clones from D10-PcMEGF were incubated in the
presence of  PcM19 IgG. These antibodies specifically in-
hibited RBC invasion of D10-PcMEGF and D10-PcM3 
parasites in a dose-dependent manner but had no effect on
parental D10. These results are consistent with the correct
expression, processing, localization and functioning of the
expected hybrid MSP-1 molecule in D10-PcMEGF para-
sites. This also reveals that the complete EGF domains of
MSP-119 are functionally conserved across distantly related
Plasmodium species.
Invasion-inhibition of Transfected P. falciparum Parasites by
Immune Sera Reveals an Important Role for MSP-119–specific
Antibodies. The availability of parasite lines that are iden-
tical except for the presence of antigenically distinct MSP-
119 domains provided a unique opportunity to address the
relative importance of MSP-119 antibodies to invasion-
inhibition by immune sera. Sets of human sera were obtained
from adults in two malaria endemic areas in Papua New
Guinea that have intense transmission rates of P. falciparum
(PNG-M and PNG-B). The majority, if not all, of these
individuals are likely to be clinically immune to P. falci-
parum malaria. Sera from six C57BL/6 mice that had been
repeatedly infected with P. chabaudi were also generated
(Pc-immune sera). To determine the presence and the
specificity of MSP-119 antibodies, each human and mouse
serum was tested in ELISA against recombinant forms of P.
falciparum MSP-119 (GST-PfM19) and P. chabaudi MSP-119
(GST-PcM19). All PNG-B sera (47/47) and most PNG-M
Figure 1. Generation of a transfected P. falciparum line containing the complete MSP-119 EGF domains from P. chabaudi in place of the endogenous
molecule. (A) Alignment of MSP-119 sequences from P. falciparum (MAD20 allele; GenBank/EMBL/DDBJ accession no. M19143) and P. chabaudi (ad-
ami DS line; GenBank/EMBL/DDBJ accession no. AF149303). The arrows indicate the sites of secondary cleavage, asterisks denote identical residues,
and dots highlight conserved residues. The disulfide bonds expected for EGF-like domains are shown (black lines). Note the absent disulfide bond in P.
chabaudi (dashed line). The nature of the gene fusions in the various MSP-1 hybrid lines is represented underneath the alignment with the dashed line rep-
resenting endogenous P. falciparum sequence and the solid line P. chabaudi sequence. (B) The plasmid pPcMEGF was constructed by ligating a DNA frag-
ment containing P. falciparum MSP-1 sequence (Target) fused to sequence encoding MSP-119 from P. chabaudi MSP-1 (dark shading) into the XhoI site
of pHC2. The predicted structure of the MSP-1 loci following integration of pPcMEGF and the location of the XbaI (X) sites used to map these loci are
shown. The location of XbaI sites unique to D10-PcM3  and D10-PfM3  are bracketed and are represented as X.Pc and X.Pf, respectively. All sizes are to
scale with the exception of the plasmid backbone (dashed line). (C) Southern blot analysis of gDNA restricted with XbaI showing that pPcMEGF had in-
tegrated into MSP-1 as predicted and that the resultant line (D10-PcMEGF) differs from the previously established lines D10-PfM3  and D10-PcM3 
(11). The 0.9-kb PfMSP-1 fragment (Target) was used to probe the blot.1407 O’Donnell et al.
sera (27/33) reacted against GST-PfM19 while only five
human sera (all from PNG-B) showed detectable cross-
reactivity with GST-PcM19 (Table I). The OD450 values
against GST-PcM19 of these five cross-reactive PNG-B
sera ranged from 0.277 to 0.900 (mean   0.451). The
remaining 42 PNG-B serum samples had OD450 values
against GST-PcM19 below 0.113.
The six mouse sera showed no reactivity to GST-PfM19
but each showed strong reactivity with GST-PcM19.
These results reveal that MSP-119 antibodies were gener-
ated in response to infection with either P. falciparum or P.
chabaudi and that these were mostly highly specific for the
homologous MSP-119 domain. The P. falciparum MSP-119
sequence of GST-PfM19 represented the “MAD20” allele;
however, each serum was also tested in parallel with a
GST-MSP-119 fusion protein comprising “KI/Wellcome”
allelic sequence (27, 29). The OD readings against this fu-
sion protein were very similar to those obtained for the
“MAD20” allele across all PNG-B and PNG-M sera (R2  
0.914). This cross-reactivity between alleles is consistent
with the findings of others (30).
Preliminary experiments in our laboratory had indicated
that D10-PcMEGF were relatively resistant to inhibition
by human sera from malaria-immune individuals. To ex-
plore this more thoroughly, all PNG-M, PNG-B, and Pc-
immune mouse sera were assessed for their ability to inhibit
invasion of D10 and D10-PcMEGF merozoites in a mi-
croscopy-based invasion inhibition assay. All sera were
tested in the one assay with the same parasite preparations
(assay 1; Fig. 3 A). PNG-B sera were relatively effective at
inhibiting invasion of parental D10 parasites with a mean
invasion of 26.7%. PNG-M sera were generally less inhibi-
tory of D10 parasites (43.1%). The difference between
PNG-B and PNG-M sera, both in invasion-inhibition and
total MSP-119 antibodies (Table I), may simply reflect a loss
of potency of PNG-M sera over relatively long-term cryo-
preservation period ( 20 yr) although this was not ex-
plored further.
Strikingly, we found that both PNG-B and PNG-M
sera were generally much less effective at inhibiting the in-
vasion of D10-PcMEGF merozoites (Fig. 3 A). Here,
mean invasion rates of 52.3 and 66.4% were obtained for
PNG-B and PNG-M, respectively, which in both cases
was  25% higher than that obtained for D10. In contrast,
Figure 2. Transfected D10-PcMEGF parasites express a functional MSP-1 chimera. (A) Western blot analysis of parasite proteins from extracted en-
riched schizont (Schiz) or merozoite (Mer) preparations of parental D10 and the D10-PcMEGF clones (PcMEGF.1 and PcMEGF.2). Proteins were sep-
arated by SDS-PAGE under nonreducing conditions, transferred to PVDF membranes, and probed with either 4H9/19 or  PcM19 antibodies as indi-
cated. The position of molecular weight standards are shown to the left and are in kD. (B) Localization of MSP-1 expressed in the transfected lines by
indirect IFA. D10-PfM3  (PfM3 ) and D10-PcMEGF.1 (PcMEGF.1) schizont-stage parasites were incubated with a mixture of 4H9/19 and  PcM19
antibodies. After incubation in the presence of a mixture of FITC-conjugated anti–mouse and rhodamine-conjugated anti–rabbit Igs, parasites were visu-
alized by microscopy. Original magnification: 1,000 . The same fields were photographed under fluorescence conditions to detect the FITC or
rhodamine fluorochromes. (C) In vitro inhibition assays of D10, D10-PcM3 , and D10-PcMEGF clones (PcMEGF.1 and PcMEGF.2) with different
concentrations of  PcM19 antibodies (IgG). Error bars represent SDs.
Table I. Reactivity in ELISA of Sera from Malaria-infected Humans and Mice Against Recombinant P. falciparum and P. chabaudi MSP-119
Mean OD450nm*
Sera n GST-PfM19 GST-PcM19 GST-PfM19 ‡ GST-PcM19 ‡
PNG-B 47 0.846   0.200 0.072   0.158 47 (100%) 5 (11%)
PNG-M 33 0.481   0.374 0.022   0.032 27 (82%) 0  (0%)
Pc immune 6 0.016   0.012 0.613   0.197 0  (0%) 6  (100%)
*Mean OD readings after subtraction of GST reactivity   SD. All sera were tested at a 1:3,200 dilution.
‡Number of sera above an OD value which equaled the mean plus three SDs of that registered in replicate assays with pooled normal human or
mouse sera where relevant. The cut-off values ranged from 0.078 to 0.180 depending on the serum/antigen combination.1408 Inhibitory MSP-119 Antibodies Are a Major Component of Malaria-immune Sera
the  Pc-immune sera were more effective at inhibiting
D10-PcMEGF (mean invasion rate 57.5%) than parental
D10 (mean invasion 73.5%). In each case, the difference in
the mean invasion rate was either significant or highly sig-
nificant (Fig. 3 A).
In an attempt to independently confirm these results, the
inhibitory potential of these sera was tested by a different
assay that utilizes [3H]hypoxanthine uptake as a measure of
parasite growth (assay 2; Fig. 3 B). In this assay, D10-
PfM3  was used as the parental control instead of D10 and
again all sera were tested together in the one assay. The re-
sults were similar to those obtained in assay 1 with D10-
PfM3  parasites more susceptible than D10-PcMEGF to
inhibition by PNG-M and PNG-B sera. Again, as in Fig. 3
A, D10-PcMEGF parasites were more susceptible than
D10-PfM3  to inhibition by Pc-immune sera. In each case,
the difference in the mean invasion rates was highly signifi-
cant. These results are consistent with a major role for
MSP-119 antibodies in invasion/growth inhibition by ma-
laria immune sera.
Fig. 4 shows inhibition results (from assay 2) that are rep-
resentative of the data obtained for individual sera. Al-
though some individual human sera did not appear to con-
tain high levels of P. falciparum MSP-119–specific inhibitory
antibodies (e.g., 938, 961, and 1,057), a major proportion
of the invasion-inhibitory component of other samples was
directed against MSP-119 (eg, 406, 604, 724). Most human
samples (59/80) showed some level of P. falciparum MSP-
119–specific inhibitory antibodies in either assay 1 or 2. All
Pc-immune sera had detectable levels of P. chabaudi MSP-
119–specific inhibitory antibodies in either assay 1 or 2. Re-
sults for the two control sera used in assay 2 are also shown
(Fig. 4). The first was a polyclonal rabbit anti–P. falciparum
AMA-1 IgG (31) used at a concentration of 250  g/ml and
the second was  PcM19 purified IgG used at a concentra-
tion of 750  g/ml. Both lines were equally susceptible to
inhibition by  AMA-1 IgG, whereas only D10-PcMEGF
was inhibited with  PcM19.
We also examined if there was any relationship between
the amounts of MSP-119–specific invasion-inhibitory anti-
body and total MSP-119 IgG. MSP-119 invasion-inhibitory
antibody in each human serum was calculated from micros-
copy-based assay by subtracting the percentage of invasion
for D10-PfM3   from the value obtained with D10-Pc-
MEGF. These values showed no correlation with the
OD450 readings obtained for each serum against GST-
PfM19 antigen (R2   0.013 and 0.0003 for PNG-M and
PNG-B sera, respectively). However, it should be noted
that four of the six PNG sera that were negative for GST-
PfM19 antibodies (at a 1:3,200 dilution) in ELISA (Table I)
also showed no detectable levels of MSP-119–specific in-
vasion-inhibitory antibodies. The amount of P. chabaudi
Figure 3. Invasion inhibition of transfected P.
falciparum parasites expressing divergent MSP-119
domains by sera from clinically immune individuals
reveals an important role for MSP-119–specific anti-
bodies. (A) Assay 1, microscopy. Microscopy-based
invasion inhibition assay involving the detection of
ring-stage D10 and D10-PcMEGF (PcMEGF) par-
asites after cultivation in the presence of each indi-
vidual serum. (B) Assay 2, hypoxanthine uptake.
Alternative invasion-inhibition assay comparing
D10-PfM3  (PfM3 ) and D10-PcMEGF parasites
using [3H]hypoxanthine uptake as a measure of par-
asite growth. Invasion is represented as either para-
sitemia (A) or counts (B) and is expressed as a per-
centage of the invasion observed in parasites
cultured in negative control sera (HNIS). The
means of samples within a serum set against each
parasite line are indicated. P values from a Student’s
t test comparing the means in each panel are shown.1409 O’Donnell et al.
MSP-119–specific inhibitory antibody present in individual
Pc-immune sera also showed no relationship to total P. cha-
baudi MSP-119–specific IgG (R2 = 0.0048).
Cocultivation Assays in the Presence of Sera from Immune
Individuals Support a Major Role for MSP-119 Antibodies in
Growth Inhibition. As an alternative means of addressing
the specificity of the inhibitory antibodies in immune sera
for MSP-119, D10-PfM3  and D10-PcMEGF parasites
were cocultivated at an equal ratio in the presence of
pooled sera. Several individual sera were pooled on the ba-
sis of the amount of anti–MSP-119–inhibitory antibody de-
termined by the inhibition assays described above. Those
with lower levels of MSP-119–specific inhibitory antibody
comprised pool 1 while those with more apparent MSP-
119–inhibitory antibody comprised pool 2. Parasites were
detected by indirect IFA using a mixture of 4H9/19 and
 PcM19 to detect D10-PfM3  and D10-PcMEGF, respec-
tively. The insert for Fig. 5 shows a typical field after incu-
bation with pooled HNIS showing similar numbers of
D10-PfM3  (green) and D10-PcMEGF (red) parasites and
illustrates the ease with which the two different lines were
visualized in the mixed culture.
Red and green fluorescent parasites were counted after 1
and 5 d of cocultivation in the presence of the different
pooled sera. After 1 d of culture, where parasites were ex-
pected to have matured but not reinvaded fresh RBCs, no
change in parasite ratio was observed with any sera. Cocul-
tivation in the presence of HNIS for 5 d also had no effect
on the ratio of the two parasite lines confirming that D10-
PfM3  and D10-PcMEGF have very similar growth rates
(Fig. 5). However, incubation of the parasite mix with
 PcM19 or Pc-immune sera had a dramatic effect on para-
site ratio with the number of D10-PfM3  parasites in 3–4-
fold excess of D10-PcMEGF. In contrast, incubation with
Figure 4. Invasion-inhibition assay with representative
individual sera from PNG-B and Pc-immune serum sets
against D10-PfM3  and D10-PcMEGF parasite lines. Sam-
ples were selected from assay 2 and represent typical exam-
ples of the inhibitory activities observed. The results ob-
tained for the control sera in assay 2, anti–P. falciparum
AMA-1 ( PfAMA1), and  PcM19 IgG are shown. Error
bars represent the range observed in duplicate samples.
Figure 5. Cocultivation of
D10-PfM3  and D10-PcMEGF
parasites in the presence of im-
mune sera confirms an important
role for MSP-119 antibodies in
invasion inhibition. Ring-stage
D10-PfM3  and D10-PcMEGF
parasites were combined at an
equal ratio and cultured in the
presence of the pooled sera indi-
cated at right. Smears from days 1
and 5 were analyzed by double-
labeling IFA. Mature stage (pig-
mented) green and red parasites
were counted in 16 fields each
containing at least 10 parasites.
The same fields were observed
by fluorescence microscopy us-
ing filters to detect the FITC or
rhodamine fluorochromes. Re-
sults are expressed as a ratio of
D10-PfM3  to D10-PcMEGF. A
representative field of parasites (at
day 3) cultured in the presence of
HNIS pool is shown (inset).1410 Inhibitory MSP-119 Antibodies Are a Major Component of Malaria-immune Sera
PNG-B–pooled sera had the opposite effect. It is important
to note that the human and mouse sera pooled on the basis
of possessing the most MSP-119–inhibitory antibody in the
aforementioned assay (Fig. 3) also exhibited the greatest
growth inhibition here.
Discussion
These data reveal a major role for MSP-119–specific anti-
bodies in mediating the invasion-inhibitory effect of sera
from P. falciparum–immune adult humans and from P. cha-
baudi–immune mice. This study was made possible by the
use of allelic replacement to derive a P. falciparum parasite
line, D10-PcMEGF, that expresses the antigenically dis-
tinct MSP-119 domain from P. chabaudi which allowed
comparisons of this line with control P. falciparum lines that
are identical to D10-PcMEGF, except for their MSP-119
domains. Our central conclusion was the consistent finding
of three different approaches. First, we used a standard mi-
croscopy-based invasion-inhibition assay to show that
D10-PcMEGF parasites were generally far less susceptible
to inhibition by P. falciparum–immune human sera than the
parent D10 line. Conversely, in this same assay, it was also
evident that D10-PcMEGF was considerable more suscep-
tible to inhibition by P. chabaudi–immune mouse sera than
D10 parasites.
Secondly, we obtained very similar results using an inde-
pendent approach that involves [3H]hypoxanthine uptake
as a measure of parasite growth. The percentage invasion
values in the [3H]hypoxanthine uptake assays were gener-
ally higher than those observed in the microscopy-based
invasion assays and sometimes values of  100% were ob-
served. This most likely reflects the fact that this assay is a
measure of parasite growth (rather than invasion) and that
parasite metabolism can differ in the presence of certain
sera, perhaps because of variations in exogenous folate lev-
els (32). However, this does not influence the finding that
D10-PcMEGF and D10-PfM3  parasites showed a dramat-
ically altered susceptibility to the same malaria-immune
sera in this assay.
Finally, we showed that malaria-immune sera exerted
strong selective effects on cocultivated P. falciparum parasite
lines that differed only in their MSP-119 domains. Growth
of the mixed D10-PcMEGF and D10-PfM3  parasite lines
in the presence of P. falciparum–immune human sera en-
riched for D10-PcMEGF. The opposite effect was ob-
served with sera from P. chabaudi–immune mice. Taken
together, all three approaches strongly indicated that MSP-
119–specific antibodies play a major invasion inhibitory role
in malaria-immune sera.
The significant contribution of just one antibody speci-
ficity to the inhibitory effect of immune sera is surprising
given that antibodies directed against a wide range of mero-
zoite antigens are known to inhibit RBC invasion. How-
ever, our results are consistent with epidemiological evi-
dence linking the presence of MSP-119–specific antibodies
to protection from clinical malaria (33–35). Together with
a considerable body of evidence highlighting the protective
efficacy of MSP-119–specific antibodies, our data supports a
significant role for MSP-119–specific invasion inhibitory
antibodies in immunity to malaria in highly exposed indi-
viduals. An examination of sera from longitudinal studies,
which involves testing individuals with a known clinical
outcome, using the assays described here would directly ad-
dress the importance of inhibitory MSP-119 antibodies to
protection from natural infection. Such a study could also
be performed in mice experimentally infected with P. cha-
baudi where clinical signs are carefully monitored.
Although our results are supportive of the development
of MSP-119–based vaccines, as with our previous study
(11), they also confirm that this domain is not tightly con-
strained by function and can accommodate considerable
antigenic diversity. Considering also that the data in this
paper suggests that MSP-119 is under considerable selection
pressure in the field, it remains somewhat of a mystery as to
why MSP-119 is relatively conserved in P. falciparum iso-
lates. It is possible that single point mutations that lead to
antibody escape result in structural instability of MSP-119
such that only certain amino acid changes are accommo-
dated or even that compensatory mutations elsewhere in
the molecule are required for the integrity of the domain to
be maintained. Such a circumstance would make it rela-
tively difficult to select for escape mutants and would ex-
plain why more extensive antigenic diversity in P. falci-
parum MSP-119 has not emerged since the relatively recent
evolutionary “bottleneck” that has been proposed for P.
falciparum (36). Allelic replacement of MSP-119 domains
provides a unique approach to map inhibitory epitopes in
polyclonal immune sera and to test if individual point mu-
tations in these epitopes leads to viable parasites that are less
susceptible to inhibitory antibodies. With respect to this, it
is worth noting that the susceptibility of P. falciparum lines
expressing partial (D10-PcM3 ) and complete (D10-Pc-
MEGF) P. chabaudi EGF domains were equally susceptible
to anti–P. chabaudi MSP-119 rabbit antisera ( PcM19; Fig.
2 C). This indicates that the inhibitory epitopes recognized
by  PcM19 are not in close proximity to the secondary
processing site.
MSP-119–specific antibodies in human immune sera in-
clude a mix of inhibitory and noninhibitory antibodies as
well as “blocking” antibodies that interfere with the inhibi-
tory effect of MSP-119 antibodies (17, 37). Hence, mea-
surement of total MSP-119 IgG is unlikely to be an accurate
correlate of immunity. Consistent with this, we found no
correlation between total MSP-119 IgG and amount of in-
hibitory MSP-119 antibodies present in the individual sera
tested in this study. The availability of a suitable in vitro
correlate of protection assay is particularly important to as-
sess the efficacy of MSP-119–based vaccines; however, the
mechanism of immunity induced by these vaccines is not
completely understood. In vaccinated Aotus monkeys, the
presence of P. falciparum MSP-1 processing–inhibitory anti-
bodies has not proven to be a good predictor of immunity
(38, 39). This has suggested that other mechanisms of im-
munity may contribute to protection from MSP-119 vac-
cines in this system, including the possibility that some1411 O’Donnell et al.
MSP-119 antibodies may interfere with an event other than
the secondary processing of MSP-1. In the rodent P. yoelii,
challenge system immunity induced by MSP-119–based
vaccines is clearly mediated by antibodies although it is not
known how these antibodies exert their protective effect
(40–42). The ability to quantitate MSP-119–specific inhibi-
tory antibodies in serum using the parasite lines and ap-
proaches described here may prove valuable for the pre-
diction of vaccine efficacy in P. falciparum or P. chabaudi
MSP-119 vaccine trials. Such an assay should be especially
useful in determining if MSP-119–inhibitory antibodies are
elicited by combination vaccines that include MSP-119.
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